Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,291 active trials259 approved drugs3,814 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,377 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05320380 | A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat | withdrawn | Phase 1 / Phase 2 | 0 | Children's Oncology GroupNETWORK | 0 | Sep 1, 2023 | clinicaltrials |
| NCT05519527 | STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL Amyloidosis | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Aug 31, 2023 | clinicaltrials |
| NCT04258683 | A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE | withdrawn | Phase 2 | 0 | Canadian Myeloma Research GroupOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT04231734 | Ketogenic Diet in Patients With Untreated Low Tumor Burden Mantle Cell Lymphoma | withdrawn | N/A | 0 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT04427228 | Single vs Multi-fraction SRS Patients on Immunotherapy(MIGRAINE) | withdrawn | Phase 2 | 0 | University of ChicagoOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT05935774 | OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | University of WashingtonOTHER | 1 | Aug 25, 2023 | clinicaltrials |
| NCT00489710 | Talabostat in Treating Patients With Metastatic Kidney Cancer | withdrawn | Phase 2 | 0 | University of NebraskaOTHER | 0 | Aug 22, 2023 | clinicaltrials |
| NCT04029038 | Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT03591614 | Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma | withdrawn | Early Phase 1 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05677373 | Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Alliance for Clinical Trials in OncologyOTHER | 0 | Aug 18, 2023 | clinicaltrials |
| NCT05918250 | mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | withdrawn | Phase 1 | 0 | ModernaTX, Inc.INDUSTRY | 2 | Aug 18, 2023 | clinicaltrials |
| NCT05098327 | Pioglitazone and Insulin Resistance in ADT | withdrawn | Phase 3 | 0 | State University of New York at BuffaloOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT05365243 | A Pilot Study to Evaluate the Use of the AMMA Portable Scalp Cooling System From Cooler Heads | withdrawn | N/A | 0 | Cooler Heads Care Inc.OTHER_GOV | 1 | Aug 15, 2023 | clinicaltrials |
| NCT05510427 | Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Aug 15, 2023 | clinicaltrials |
| NCT00455039 | INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients | withdrawn | Phase 1 / Phase 2 | 0 | University of New MexicoOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT00816413 | Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of NebraskaOTHER | 0 | Aug 14, 2023 | clinicaltrials |
| NCT00863824 | Clearance of NNAL and Cotinine From Second-hand Smoke in Hair and Urine(NNAL) | withdrawn | — | 0 | University of NebraskaOTHER | 0 | Aug 14, 2023 | clinicaltrials |
| NCT01555632 | Atorvastatin Calcium in Preventing Metabolic Syndrome in Prostate Cancer Patients Receiving Androgen-Deprivation Therapy | withdrawn | N/A | 0 | University of NebraskaOTHER | 0 | Aug 14, 2023 | clinicaltrials |
| NCT05729139 | Cemiplimab/Peg-Interferon-α in Advanced CSCC | withdrawn | Phase 1 | 0 | Baptist Health South FloridaOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT00488605 | H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis | withdrawn | Phase 3 | 0 | University of New MexicoOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT04922112 | Sleep Apnea in Head and Neck Cancer Patients at the University of Colorado(OSA-HN) | withdrawn | N/A | 0 | University of Colorado, DenverOTHER | 1 | Aug 2, 2023 | clinicaltrials |
| NCT04901299 | Fulvestrant + Neratinib In Breast Cancer(HER2-Signal) | withdrawn | Phase 2 | 0 | Massachusetts General HospitalOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT04210726 | Effect of Salt Solution Immersion Bath on Cancer in Vivo. | withdrawn | N/A | 0 | Rafik BatroussyOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05791097 | Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.(AdvanTIG-306) | withdrawn | Phase 3 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Jul 24, 2023 | clinicaltrials |
| NCT05809895 | Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer(AdvanTIG-211) | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Jul 24, 2023 | clinicaltrials |
| NCT03932318 | Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients | withdrawn | Phase 1 / Phase 2 | 0 | Actinium PharmaceuticalsINDUSTRY | 0 | Jul 20, 2023 | clinicaltrials |
| NCT05171062 | Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung Cancer | withdrawn | Phase 1 | 0 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Jul 20, 2023 | clinicaltrials |
| NCT05653531 | Clinical Significance of Hepatic Biomarkers in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors(HEPATICI) | withdrawn | N/A | 0 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jul 20, 2023 | clinicaltrials |
| NCT04591028 | A Study to Evaluate Indocyanine Green Lymphangiography to Improve Lymphadenectomy in Gastric Cancer Patients | withdrawn | Phase 4 | 0 | Mayo ClinicOTHER | 1 | Jul 19, 2023 | clinicaltrials |
| NCT05951842 | Anesthesia, TIVA, Balanced Anesthesia, NK Cell | withdrawn | N/A | 0 | Gangnam Severance HospitalOTHER | 0 | Jul 19, 2023 | clinicaltrials |
| NCT05400577 | Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC | withdrawn | Phase 2 | 0 | Fox Chase Cancer CenterOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT05109052 | Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | University of RochesterOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT03722498 | Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT04781374 | Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer | withdrawn | Phase 2 | 0 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT05191004 | Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC | withdrawn | Phase 1 / Phase 2 | 0 | Nuvation Bio Inc.INDUSTRY | 1 | Jul 11, 2023 | clinicaltrials |
| NCT05255666 | Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM) | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Jul 11, 2023 | clinicaltrials |
| NCT05604417 | Zandelisib + Tazemetostat in R/R Follicular Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Jacob Soumerai, MDOTHER | 0 | Jul 7, 2023 | clinicaltrials |
| NCT05934097 | FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma | withdrawn | Phase 1 | 0 | Fate TherapeuticsINDUSTRY | 0 | Jul 6, 2023 | clinicaltrials |
| NCT00298064 | Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer | withdrawn | N/A | 0 | University of New MexicoOTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT04114422 | A Seven-day Preoperative Exercise Training Program in People With Abdominal Cancer | withdrawn | N/A | 0 | Universidade Cidade de Sao PauloOTHER | 1 | Jul 3, 2023 | clinicaltrials |
| NCT04466917 | A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer | withdrawn | Phase 3 | 0 | AmgenINDUSTRY | 0 | Jul 3, 2023 | clinicaltrials |
| NCT05216120 | Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas | withdrawn | Phase 2 | 0 | HonorHealth Research InstituteOTHER | 1 | Jul 3, 2023 | clinicaltrials |
| NCT05363644 | BioDFence® G3 For Full Nerve-Sparing Robotic-Assisted Radical Prostatectomy | withdrawn | Phase 3 | 0 | AdventHealthOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT05614453 | Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy(ITTACC) | withdrawn | Phase 2 | 0 | Australia New Zealand Gynaecological Oncology GroupOTHER | 0 | Jun 29, 2023 | clinicaltrials |
| NCT02515513 | The Role of Muscle Cachexia in Pancreatic Cancer | withdrawn | N/A | 0 | University of FloridaOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT04252612 | Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study | withdrawn | Early Phase 1 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT03745352 | Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Jun 27, 2023 | clinicaltrials |
| NCT03552796 | sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer | withdrawn | Phase 1 | 0 | University of Southern CaliforniaOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT05063357 | 131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma | withdrawn | Phase 1 | 0 | Y-mAbs TherapeuticsINDUSTRY | 0 | Jun 26, 2023 | clinicaltrials |
| NCT04995978 | Insulin Resistance and Androgen Deprivation Therapy | withdrawn | Phase 2 | 0 | St. Louis UniversityOTHER | 1 | Jun 23, 2023 | clinicaltrials |
Data updated 24 days agoSource updated Sep 1, 2023source: clinicaltrials